SORT1 and frontotemporal dementia: Accordingly, a human monoclonal antibody directed against sortilin is currently in clinical trials (19, 20, 21) to block sortilin-mediated PGRN clearance in subjects at risk for or with FTD due to PGRN deficiency caused by heterozygous mutations in the GRN gene (15, 16).